Jeffrey Hung
Stock Analyst at Morgan Stanley
(4.36)
# 353
Out of 5,131 analysts
230
Total ratings
53.24%
Success rate
17.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTNM Contineum Therapeutics | Downgrades: Equal-Weight | $23 → $14 | $14.49 | -3.38% | 5 | Jan 8, 2026 | |
| NBIX Neurocrine Biosciences | Downgrades: Equal-Weight | $173 → $175 | $124.12 | +40.99% | 32 | Jan 8, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Overweight | $77 → $80 | $42.67 | +87.49% | 4 | Jan 6, 2026 | |
| CYTK Cytokinetics | Maintains: Overweight | $65 → $71 | $66.26 | +7.15% | 14 | Dec 23, 2025 | |
| BIOA BioAge Labs | Upgrades: Equal-Weight | $5 → $12 | $19.57 | -38.68% | 3 | Dec 8, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $185 → $205 | $166.27 | +23.29% | 12 | Nov 17, 2025 | |
| ENGN enGene Holdings | Maintains: Overweight | $18 → $19 | $9.78 | +94.27% | 5 | Nov 12, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $122 → $129 | $98.07 | +31.54% | 14 | Oct 16, 2025 | |
| CGON CG Oncology | Maintains: Overweight | $56 → $79 | $51.50 | +53.40% | 5 | Sep 17, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $76 → $71 | $69.45 | +2.23% | 13 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $28 | $11.59 | +141.59% | 7 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $4 → $2 | $12.00 | -83.33% | 4 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $13 | $5.24 | +148.09% | 6 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $102 → $108 | $14.31 | +654.72% | 5 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $55 | $20.52 | +168.03% | 9 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $24 | $22.03 | +8.94% | 25 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $55.95 | +51.92% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $24.71 | +9.29% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $4.72 | +641.53% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $2.23 | +79.37% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $1.56 | +156.41% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $4.93 | +183.98% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $3.99 | +25.31% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $3.43 | -12.54% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $1.27 | +687.40% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $43.92 | -49.91% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $11.36 | +1,207.22% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $0.61 | +9,745.75% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $3.40 | +76.47% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $696 → $648 | $13.10 | +4,846.56% | 6 | May 8, 2020 |
Contineum Therapeutics
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $23 → $14
Current: $14.49
Upside: -3.38%
Neurocrine Biosciences
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $173 → $175
Current: $124.12
Upside: +40.99%
Crinetics Pharmaceuticals
Jan 6, 2026
Maintains: Overweight
Price Target: $77 → $80
Current: $42.67
Upside: +87.49%
Cytokinetics
Dec 23, 2025
Maintains: Overweight
Price Target: $65 → $71
Current: $66.26
Upside: +7.15%
BioAge Labs
Dec 8, 2025
Upgrades: Equal-Weight
Price Target: $5 → $12
Current: $19.57
Upside: -38.68%
Jazz Pharmaceuticals
Nov 17, 2025
Maintains: Overweight
Price Target: $185 → $205
Current: $166.27
Upside: +23.29%
enGene Holdings
Nov 12, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $9.78
Upside: +94.27%
Rhythm Pharmaceuticals
Oct 16, 2025
Maintains: Overweight
Price Target: $122 → $129
Current: $98.07
Upside: +31.54%
CG Oncology
Sep 17, 2025
Maintains: Overweight
Price Target: $56 → $79
Current: $51.50
Upside: +53.40%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $76 → $71
Current: $69.45
Upside: +2.23%
Aug 18, 2025
Maintains: Overweight
Price Target: $35 → $28
Current: $11.59
Upside: +141.59%
Aug 18, 2025
Downgrades: Equal-Weight
Price Target: $4 → $2
Current: $12.00
Upside: -83.33%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $17 → $13
Current: $5.24
Upside: +148.09%
Jul 17, 2025
Upgrades: Overweight
Price Target: $102 → $108
Current: $14.31
Upside: +654.72%
Jul 14, 2025
Maintains: Overweight
Price Target: $65 → $55
Current: $20.52
Upside: +168.03%
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $22.03
Upside: +8.94%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $55.95
Upside: +51.92%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $24.71
Upside: +9.29%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $4.72
Upside: +641.53%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $2.23
Upside: +79.37%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $1.56
Upside: +156.41%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $4.93
Upside: +183.98%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $3.99
Upside: +25.31%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $3.43
Upside: -12.54%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $1.27
Upside: +687.40%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $43.92
Upside: -49.91%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $11.36
Upside: +1,207.22%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $0.61
Upside: +9,745.75%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $3.40
Upside: +76.47%
May 8, 2020
Maintains: Overweight
Price Target: $696 → $648
Current: $13.10
Upside: +4,846.56%